The U.S. Food and Drug Administration in 2020 announced an involuntary recall of heartburn medication ranitidine, including Zantac, citing the presence of a possible carcinogen.
Litigation against Zantac manufacturers filed in the state of New York will move forward as a consolidated action, a panel has ruled.
The New York State Litigation Coordinating Panel on Thursday combined some 40 active cases for pre-trial litigation in New York County. Any future ranitidine-related personal injury cases filed in the state will proceed under this same action, the ruling said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
